NCT02521363View on ClinicalTrials.gov

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 24, 2015

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Breast Cancer
Interventions
DEVICE

KIBUR MICRODEVICE

This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.

DRUG

anthracycline and taxane based chemotherapy

Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan-Kettering Cancer Center at Commack, Commack

07920

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02521363 - Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter